Comment from Advarra, Inc.

Summary: Advarra, Incorporated, a company providing research review and compliance services, submitted comments supporting the draft guidance on responding to FDA Form 483 observations. They propose specific technical revisions, including adding footnotes for disagreements, clarifying terminology like CAPA and RCA, and suggesting additional bullet points to improve the clarity and practical application of the guidance for manufacturing facilities.